News from REMEDY

Interstitial lung disease (ILD) is one of the most serious complications of systemic rheumatic diseases. Often, clear symptoms are not experienced until significant lung damage has occurred. Now, research is underway to see if home-based digital monitoring can help detect and treat the disease earlier.

Treatment of serious autoimmune diseases has improved significantly in recent decades. However, there are patients who do not achieve lasting recovery, no matter how advanced the treatment is. This has created interest in CAR-T in rheumatology.

Rheumatologists at Diakonhjemmet Hospital are alone in Norway in using a gentle technique, which gives researchers direct access to the core of the disease.

Professor Emeritus Tore Kvien has been awarded the Honorary Award of the Year during the first awarding of the "Award for Outstanding Contribution to Clinical Studies". With the award, the organizers honor a professional who has left a lasting mark over time. For Diakonhjemmet Hospital, it is a celebration of an environment that has combined patient care and clinical research for decades.

South-Eastern Health RHF provides one million kroner for further development of digital patient tools at Diakonhjemmet Hospital and REMEDY.  

REMEDY has been nominated for "Center of the Year" for the first-ever "Award for Outstanding Effort in Clinical Studies."

Researchers are investigating whether a drug used for other diseases can relieve hand osteoarthritis in patients who do not receive enough help from current treatment – ​​information, exercise and painkillers.

The year was characterized by high research activity, new projects, important milestones and solid external funding.

The Unit for Health Services Research and Innovation (EHI) at Diakonhjemmet Hospital is one of three finalists for the Innovative Environment of the Year. The award for outstanding efforts in clinical studies will be presented for the very first time on January 29, 2026.